Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 63

1.

Cochlear implants: Insertion assessment by computed tomography.

Menegatti Pavan AL, Alves AFF, Giacomini G, Altemani JMC, Castilho AM, Lauria RA, da Silva VAR, Guimarães AC, de Pina DR.

Am J Otolaryngol. 2018 Jul - Aug;39(4):431-435. doi: 10.1016/j.amjoto.2018.04.009. Epub 2018 Apr 14.

PMID:
29685378
2.

Laparoscopic surgery in the treatment of stage I adult granulosa cells tumors of the ovary: Results from the MITO-9 study.

Bergamini A, Ferrandina G, Candiani M, Cormio G, Giorda G, Lauria R, Perrone AM, Scarfone G, Breda E, Savarese A, Frigerio L, Gadducci A, Mascilini F, Maneschi F, Cassani C, Marchetti C, Cecere SC, Biglia N, De Giorgi U, Raspagliesi F, Lorusso D, Mangili G.

Eur J Surg Oncol. 2018 Jun;44(6):766-770. doi: 10.1016/j.ejso.2018.03.001. Epub 2018 Mar 10.

PMID:
29576462
3.

Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial.

De Placido S, Gallo C, De Laurentiis M, Bisagni G, Arpino G, Sarobba MG, Riccardi F, Russo A, Del Mastro L, Cogoni AA, Cognetti F, Gori S, Foglietta J, Frassoldati A, Amoroso D, Laudadio L, Moscetti L, Montemurro F, Verusio C, Bernardo A, Lorusso V, Gravina A, Moretti G, Lauria R, Lai A, Mocerino C, Rizzo S, Nuzzo F, Carlini P, Perrone F; GIM Investigators.

Lancet Oncol. 2018 Apr;19(4):474-485. doi: 10.1016/S1470-2045(18)30116-5. Epub 2018 Feb 23. Erratum in: Lancet Oncol. 2018 Apr;19(4):e184.

PMID:
29482983
4.

It is no longer the time to disregard thyroid metastases from breast cancer: a case report and review of the literature.

Pensabene M, Stanzione B, Cerillo I, Ciancia G, Cozzolino I, Ruocco R, Condello C, Di Lorenzo G, Giuliano M, Forestieri V, Arpino G, De Placido S, Lauria R.

BMC Cancer. 2018 Feb 6;18(1):146. doi: 10.1186/s12885-018-4054-x.

5.

Combined effect of obesity and diabetes on early breast cancer outcome: a prospective observational study.

Buono G, Crispo A, Giuliano M, De Angelis C, Schettini F, Forestieri V, Lauria R, Pensabene M, De Laurentiis M, Augustin LSA, Amore A, D'Aiuto M, Tortoriello R, Accurso A, Cavalcanti E, Botti G, Montella M, De Placido S, Arpino G.

Oncotarget. 2017 Dec 5;8(70):115709-115717. doi: 10.18632/oncotarget.22977. eCollection 2017 Dec 29.

6.

Fractional microablative CO2 laser in breast cancer survivors affected by iatrogenic vulvovaginal atrophy after failure of nonestrogenic local treatments: a retrospective study.

Pagano T, De Rosa P, Vallone R, Schettini F, Arpino G, Giuliano M, Lauria R, De Santo I, Conforti A, Gallo A, Nazzaro G, De Placido S, Locci M, De Placido G.

Menopause. 2018 Jun;25(6):657-662. doi: 10.1097/GME.0000000000001053.

PMID:
29286986
7.

Pretreatment Serum Concentration of Vitamin D and Breast Cancer Characteristics: A Prospective Observational Mediterranean Study.

Buono G, Giuliano M, De Angelis C, Lauria R, Forestieri V, Pensabene M, Bruzzese D, De Placido S, Arpino G.

Clin Breast Cancer. 2017 Nov;17(7):559-563. doi: 10.1016/j.clbc.2017.05.007. Epub 2017 May 19.

PMID:
28601383
8.

Tumor characteristics and prognosis in familial breast cancer.

Arpino G, Pensabene M, Condello C, Ruocco R, Cerillo I, Lauria R, Forestieri V, Giuliano M, De Angelis C, Montella M, Crispo A, De Placido S.

BMC Cancer. 2016 Nov 29;16(1):924.

9.

Long-term survival and BRCA status in male breast cancer: a retrospective single-center analysis.

Gargiulo P, Pensabene M, Milano M, Arpino G, Giuliano M, Forestieri V, Condello C, Lauria R, De Placido S.

BMC Cancer. 2016 Jul 4;16:375. doi: 10.1186/s12885-016-2414-y.

10.

Metabolic and anthropometric changes in early breast cancer patients receiving adjuvant therapy.

Arpino G, De Angelis C, Buono G, Colao A, Giuliano M, Malgieri S, Cicala S, De Laurentiis M, Accurso A, Crispo A, Limite G, Lauria R, Veneziani BM, Forestieri V, Bruzzese D, De Placido S.

Breast Cancer Res Treat. 2015 Nov;154(1):127-32. doi: 10.1007/s10549-015-3586-x. Epub 2015 Sep 30.

11.

Bone involvement by adenocarcinoma of the uterine cervix: a rare entity.

Crisci V, Mainenti PP, Corvino F, Lauria R, Maurea S.

Pol J Radiol. 2015 Feb 14;80:81-4. doi: 10.12659/PJR.892369. eCollection 2015.

12.

Weekly docetaxel versus CMF as adjuvant chemotherapy for older women with early breast cancer: final results of the randomized phase III ELDA trial.

Perrone F, Nuzzo F, Di Rella F, Gravina A, Iodice G, Labonia V, Landi G, Pacilio C, Rossi E, De Laurentiis M, D'Aiuto M, Botti G, Forestieri V, Lauria R, De Placido S, Tinessa V, Daniele B, Gori S, Colantuoni G, Barni S, Riccardi F, De Maio E, Montanino A, Morabito A, Daniele G, Di Maio M, Piccirillo MC, Signoriello S, Gallo C, de Matteis A.

Ann Oncol. 2015 Apr;26(4):675-82. doi: 10.1093/annonc/mdu564. Epub 2014 Dec 8.

PMID:
25488686
13.

Extensive Frontoparietal Abscess: Complication of Frontal Sinusitis (Pott's Puffy Tumor).

Lauria RA, Laffitte Fernandes F, Brito TP, Pereira PS, Chone CT.

Case Rep Otolaryngol. 2014;2014:632464. doi: 10.1155/2014/632464. Epub 2014 May 25.

14.

Carboplatin plus paclitaxel once a week versus every 3 weeks in patients with advanced ovarian cancer (MITO-7): a randomised, multicentre, open-label, phase 3 trial.

Pignata S, Scambia G, Katsaros D, Gallo C, Pujade-Lauraine E, De Placido S, Bologna A, Weber B, Raspagliesi F, Panici PB, Cormio G, Sorio R, Cavazzini MG, Ferrandina G, Breda E, Murgia V, Sacco C, Cinieri S, Salutari V, Ricci C, Pisano C, Greggi S, Lauria R, Lorusso D, Marchetti C, Selvaggi L, Signoriello S, Piccirillo MC, Di Maio M, Perrone F; Multicentre Italian Trials in Ovarian cancer (MITO-7); Groupe d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens et du sein (GINECO); Mario Negri Gynecologic Oncology (MaNGO); European Network of Gynaecological Oncological Trial Groups (ENGOT-OV-10); Gynecologic Cancer InterGroup (GCIG) Investigators.

Lancet Oncol. 2014 Apr;15(4):396-405. doi: 10.1016/S1470-2045(14)70049-X. Epub 2014 Feb 28.

PMID:
24582486
15.

Long-term disease control with lapatinib and capecitabine in a patient with HER2-positive metastatic breast cancer pretreated with trastuzumab and trastuzumab-emtansine.

De Angelis C, Milano M, Gargiulo P, Stanzione B, Forestieri V, Lauria R, Pensabene M, D'Arco F, De Placido S, Arpino G.

Tumori. 2013 May-Jun;99(3):e131-3. doi: 10.1700/1334.14822.

PMID:
24158083
16.

Decision making in borderline ovarian tumors: report of a rare case of mesosigma psammocarcinoma.

Grimaldi L, Danzi M, Reggio S, Pannullo M, Danzi R, Lauria R.

Ann Ital Chir. 2013 Sep 3;84(ePub). pii: S2239253X13021609.

PMID:
23995281
17.

Recurrent granulosa cell tumors (GCTs) of the ovary: a MITO-9 retrospective study.

Mangili G, Sigismondi C, Frigerio L, Candiani M, Savarese A, Giorda G, Lauria R, Tamberi S, Greggi S, Lorusso D.

Gynecol Oncol. 2013 Jul;130(1):38-42. doi: 10.1016/j.ygyno.2013.04.047. Epub 2013 Apr 25.

PMID:
23623833
18.

EMPACT syndrome associated with phenobarbital.

Fabbrocini G, Panariello L, Pensabene M, Lauria R, Matano E, Martellotta D, Bianca D, De Placido S, Ayala F.

Dermatitis. 2013 Jan-Feb;24(1):37-9. doi: 10.1097/DER.0b013e31827ede32.

PMID:
23340399
19.

Ovarian metastasis following gallbladder carcinoma: a case report.

Carlomagno C, Insabato L, Bifulco G, De Placido S, Lauria R.

Eur J Gynaecol Oncol. 2010;31(2):219-21.

PMID:
20527247
20.

Urinary estrogen metabolites and prostate cancer: a case-control study and meta-analysis.

Barba M, Yang L, Schünemann HJ, Sperati F, Grioni S, Stranges S, Westerlind KC, Blandino G, Gallucci M, Lauria R, Malorni L, Muti P.

J Exp Clin Cancer Res. 2009 Oct 8;28:135. doi: 10.1186/1756-9966-28-135.

21.

A phase II study of capecitabine in the treatment of ovarian cancer resistant or refractory to platinum therapy: a multicentre Italian trial in ovarian cancer (MITO-6) trial.

Pisano C, Morabito A, Sorio R, Breda E, Lauria R, Gebbia V, Scaltriti L, Scalone S, Zagonel V, Greggi S, Beneduce G, Losito S, Gallo C, Di Maio M, Forestieri V, Pignata S.

Cancer Chemother Pharmacol. 2009 Oct;64(5):1021-7. doi: 10.1007/s00280-009-0958-0. Epub 2009 Mar 6.

PMID:
19266200
22.

Poor outcome of elderly patients with platinum-sensitive recurrent ovarian cancer: results from the SOCRATES retrospective study.

Pignata S, Ferrandina G, Scarfone G, Scollo P, Odicino F, Cormio G, Katsaros D, Frigerio L, Mereu L, Ghezzi F, Manzione L, Lauria R, Breda E, Alletti DG, Ballardini M, Vernaglia A, Sorio R, Tumolo S, Musso P, Magni G, Pisano C, Morabito A.

Crit Rev Oncol Hematol. 2009 Sep;71(3):233-41. doi: 10.1016/j.critrevonc.2008.12.010. Epub 2009 Jan 28.

PMID:
19179095
23.

Activity of chemotherapy in mucinous ovarian cancer with a recurrence free interval of more than 6 months: results from the SOCRATES retrospective study.

Pignata S, Ferrandina G, Scarfone G, Scollo P, Odicino F, Cormio G, Katsaros D, Villa A, Mereu L, Ghezzi F, Manzione L, Lauria R, Breda E, Alletti DG, Ballardini M, Lombardi AV, Sorio R, Mangili G, Priolo D, Magni G, Morabito A.

BMC Cancer. 2008 Sep 1;8:252. doi: 10.1186/1471-2407-8-252.

24.

Central nervous system metastases in a cohort of metastatic breast cancer patients treated with trastuzumab.

Montagna E, Cancello G, D'Agostino D, Lauria R, Forestieri V, Esposito A, Silvestro L, Accurso A, De Placido S, De Laurentiis M.

Cancer Chemother Pharmacol. 2009 Jan;63(2):275-80. doi: 10.1007/s00280-008-0737-3. Epub 2008 Apr 1.

PMID:
18379783
25.

Edentulous patients' knowledge of dental hygiene and care of prostheses.

de Castellucci Barbosa L, Ferreira MR, de Carvalho Calabrich CF, Viana AC, de Lemos MC, Lauria RA.

Gerodontology. 2008 Jun;25(2):99-106. doi: 10.1111/j.1741-2358.2007.00190.x. Epub 2008 Mar 5.

PMID:
18328074
26.

Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials.

De Laurentiis M, Cancello G, D'Agostino D, Giuliano M, Giordano A, Montagna E, Lauria R, Forestieri V, Esposito A, Silvestro L, Pennacchio R, Criscitiello C, Montanino A, Limite G, Bianco AR, De Placido S.

J Clin Oncol. 2008 Jan 1;26(1):44-53. doi: 10.1200/JCO.2007.11.3787.

PMID:
18165639
27.

Weekly docetaxel versus CMF as adjuvant chemotherapy for elderly breast cancer patients: safety data from the multicentre phase 3 randomised ELDA trial.

Nuzzo F, Morabito A, De Maio E, Di Rella F, Gravina A, Labonia V, Landi G, Pacilio C, Piccirillo MC, Rossi E, D'Aiuto G, Thomas R, Gori S, Colozza M, De Placido S, Lauria R, Signoriello G, Gallo C, Perrone F, de Matteis A.

Crit Rev Oncol Hematol. 2008 May;66(2):171-80. Epub 2007 Dec 21.

PMID:
18160303
28.

Extending the platinum-free interval with a non-platinum therapy in platinum-sensitive recurrent ovarian cancer. Results from the SOCRATES Retrospective Study.

Pignata S, Ferrandina G, Scarfone G, Scollo P, Odicino F, Selvaggi L, Katsaros D, Frigerio L, Mereu L, Ghezzi F, Manzione L, Lauria R, Breda E, Marforio G, Ballardini M, Lombardi AV, Sorio R, Tumolo S, Costa B, Magni G, Perrone F, Favalli G; SOCRATES and MITO investigators.

Oncology. 2006;71(5-6):320-6. Epub 2007 Sep 18.

PMID:
17878745
29.

Erythrocyte membrane phospholipid composition as a biomarker of dietary fat.

Fuhrman BJ, Barba M, Krogh V, Micheli A, Pala V, Lauria R, Chajes V, Riboli E, Sieri S, Berrino F, Muti P.

Ann Nutr Metab. 2006;50(2):95-102. Epub 2005 Dec 21.

PMID:
16373991
30.

A meta-analysis on the interaction between HER-2 expression and response to endocrine treatment in advanced breast cancer.

De Laurentiis M, Arpino G, Massarelli E, Ruggiero A, Carlomagno C, Ciardiello F, Tortora G, D'Agostino D, Caputo F, Cancello G, Montagna E, Malorni L, Zinno L, Lauria R, Bianco AR, De Placido S.

Clin Cancer Res. 2005 Jul 1;11(13):4741-8.

31.

A randomised factorial trial of sequential doxorubicin and CMF vs CMF and chemotherapy alone vs chemotherapy followed by goserelin plus tamoxifen as adjuvant treatment of node-positive breast cancer.

De Placido S, De Laurentiis M, De Lena M, Lorusso V, Paradiso A, D'Aprile M, Pistillucci G, Farris A, Sarobba MG, Palazzo S, Manzione L, Adamo V, Palmeri S, Ferraù F, Lauria R, Pagliarulo C, Petrella G, Limite G, Costanzo R, Bianco AR; GOCSI Cooperative Group.

Br J Cancer. 2005 Feb 14;92(3):467-74.

32.

Topotecan compared with no therapy after response to surgery and carboplatin/paclitaxel in patients with ovarian cancer: Multicenter Italian Trials in Ovarian Cancer (MITO-1) randomized study.

De Placido S, Scambia G, Di Vagno G, Naglieri E, Lombardi AV, Biamonte R, Marinaccio M, Cartenì G, Manzione L, Febbraro A, De Matteis A, Gasparini G, Valerio MR, Danese S, Perrone F, Lauria R, De Laurentiis M, Greggi S, Gallo C, Pignata S.

J Clin Oncol. 2004 Jul 1;22(13):2635-42.

PMID:
15226331
33.

Is there a standard chemotherapeutic regimen for hormone-refractory prostate cancer? Present and future approaches in the management of the disease.

Di Lorenzo G, Autorino R, De Laurentiis M, Bianco R, Lauria R, Giordano A, De Sio M, D'Armiento M, Bianco AR, De Placido S.

Tumori. 2003 Jul-Aug;89(4):349-60. Review.

PMID:
14606635
34.

Second-line chemotherapy with a hybrid-alternating regimen of bolus 5FU modulated by methotrexate and infusional 5FU modulated by folinic acid in patients with metastatic colorectal cancer pretreated with 5FU. A phase 2 study.

Carlomagno C, Lauria R, De Laurentiis M, Arpino G, Massarelli E, Ferrara C, Milano A, Vernaglia Lombardi A, Costanzo R, Catalano G, Bianco AR, De Placido S.

Oncology. 2002;63(3):219-25.

PMID:
12381900
35.

Carboplatin, cisplatin and paclitaxel in the treatment of patients with epithelial ovarian cancer.

De Placido S, Tramontana S, Ferrari E, De Matteis A, Lauria R, Perrone F, Bianco AR, Gallo C, Ricchi P, De Placido G, Pignata S; GCTO (Gruppo Campano Sui Tumori Dell'Ovaio).

Anticancer Res. 2000 Sep-Oct;20(5C):4023-9.

PMID:
11268496
36.

Vinorelbine + mitomycin C as second-line treatment of metastatic breast cancer: a two-stage phase 2 study.

De Placido S, Lauria R, Perrone F, Vernaglia Lombardi A, Carlomagno C, Varriale E, Costanzo R, Leo L, De Laurentiis M, Bianco AR.

Oncology. 2000;58(1):8-14.

PMID:
10644934
37.

The impact of schedule on acute toxicity and dose-intensity of high-dose chemotherapy with epirubicin and cyclophosphamide plus colony stimulating factors in advanced breast cancer.

De Placido S, Lauria R, Carlomagno C, Perrone F, De Laurentiis M, Gallo C, Martignetti A, Bellelli T, Limite G, Petrella G, Bianco AR.

Int J Oncol. 1999 Aug;15(2):339-46.

PMID:
10402245
38.

A phase I study of paclitaxel and epirubicin, without and with filgrastim, for the treatment of platinum-resistant advanced ovarian cancer.

Lauria R, Ferrari E, Tramontana S, Morabito A, Perrone F, Maffeo A, Fiorentino R, Casella G, Iodice F, Ricchi P, Carlomagno C, Varriale E, De Placido G, De Placido S, Bianco AR, Pignata S.

Oncology. 1999;56(4):267-73.

PMID:
10343189
39.

[A facilitated technique for donor hepatectomy: experimental study in the pig].

Gruttadauria S, Marino G, Gentile A, La Terra S, Costanzo C, Barbagallo O, Lauria R, Chiaramida D, Sgroi AV, Libra S, Fonti A, Gruttadauria G.

G Chir. 1998 Nov-Dec;19(11-12):485-8. Italian.

PMID:
9882955
40.

Tailored therapy for aggressive non-Hodgkin's lymphoma: results of a phase II study with a long-term follow-up.

Palmieri G, Morabito A, Rea A, Biondi E, Lauria R, Matano E, Pagliarulo C, Montesarchio V, Tagliaferri P, Bianco AR.

Int J Oncol. 1998 Jul;13(1):121-7.

PMID:
9625813
41.

Phase I study of carboplatin, cisplatin, and cyclophosphamide without and with lenograstim for the treatment of ovarian cancer.

Pignata S, Lauria R, Perrone F, Ferrari E, Biondi E, Maffeo A, Morabito A, Graziano R, Carlomagno C, Deplacido G, Gallo C, Bianco A, Pergola M, Deplacido S.

Int J Oncol. 1997 Jul;11(1):175-80.

PMID:
21528198
42.

c-erb B2 overexpression decreases the benefit of adjuvant tamoxifen in early-stage breast cancer without axillary lymph node metastases.

Carlomagno C, Perrone F, Gallo C, De Laurentiis M, Lauria R, Morabito A, Pettinato G, Panico L, D'Antonio A, Bianco AR, De Placido S.

J Clin Oncol. 1996 Oct;14(10):2702-8.

PMID:
8874330
43.

Maintenance therapy with recombinant interferon alpha-2B (alpha IFN) in prognostically unfavourable aggressive non-Hodgkin's lymphomas (NHL).

Palmieri G, Morabito A, Rea A, Lauria R, Montesarchio V, Biondi E, Caraglia M, Tagliaferri P, Bianco A.

Oncol Rep. 1996 Jul;3(4):733-5.

PMID:
21594444
44.

Selecting high-risk early breast cancer patients: what to add to the number of metastatic nodes?

Perrone F, Carlomagno C, Lauria R, De Laurentiis M, Morabito A, Panico L, Pettinato G, Petrella G, Gallo C, Bianco AR, De Placido S.

Eur J Cancer. 1996 Jan;32A(1):41-6.

PMID:
8695239
45.

First-line systemic therapy for metastatic breast cancer and management of pleural effusion.

Perrone F, Carlomagno C, De Placido S, Lauria R, Morabito A, Bianco AR.

Ann Oncol. 1995 Dec;6(10):1033-43. Review. No abstract available.

PMID:
8750157
46.

The prognostic value of lymphatic and blood vessel invasion in operable breast cancer.

Lauria R, Perrone F, Carlomagno C, De Laurentiis M, Morabito A, Gallo C, Varriale E, Pettinato G, Panico L, Petrella G, et al.

Cancer. 1995 Nov 15;76(10):1772-8.

PMID:
8625046
47.

Adjuvant chemoendocrine therapy for early breast-cancer - is it worthwhile - (review).

Perrone F, Deplacido S, Gallo C, Carlomagno C, Lauria R, Bianco A.

Int J Oncol. 1995 Nov;7(5):1129-37.

PMID:
21552942
48.

Prognostic significance of necrosis, elastosis, fibrosis and inflammatory cell reaction in operable breast cancer.

Carlomagno C, Perrone F, Lauria R, de Laurentiis M, Gallo C, Morabito A, Pettinato G, Panico L, Bellelli T, Apicella A, et al.

Oncology. 1995 Jul-Aug;52(4):272-7.

PMID:
7777238
49.

Interleukin-2-induced renal dysfunction in cancer patients is reversed by low-dose dopamine infusion.

Memoli B, De Nicola L, Libetta C, Scialò A, Pacchiano G, Romano P, Palmieri G, Morabito A, Lauria R, Conte G, et al.

Am J Kidney Dis. 1995 Jul;26(1):27-33.

PMID:
7611264
50.

CMF vs alternating CMF/EV in the adjuvant treatment of operable breast cancer. A single centre randomised clinical trial (Naples GUN-3 study).

De Placido S, Perrone F, Carlomagno C, Morabito A, Pagliarulo C, Lauria R, Marinelli A, De Laurentiis M, Varriale E, Petrella G, et al.

Br J Cancer. 1995 Jun;71(6):1283-7.

Supplemental Content

Loading ...
Support Center